Autor/in Blauvelt, A 1 Gooderham, M 1 Lowry, S Mendelsohn, A 1 Papp, K 1 Parno, J 1 Reich, K 1 Sofen, H 1 Tyring, S Zhao, Y alle zeigenListe einklappen
Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials Blauvelt, A Sofen, H Papp, K Gooderham, M Tyring, S Zhao, Y Lowry, S 2019 - Forschungsinformationssystem des UKE
